Morsa Images/DigitalVision via Getty Images Quest Diagnostics ( NYSE: DGX ) has completed its acquisition of PathAI Diagnostics from PathAI. The deal was first announced in May. PathAI Diagnostics' digitized laboratory has been rebranded as AmeriPath.
It will become the national AI and digital R&D and solutions center supporting Quest's specialty pathology businesses, AmeriPath and Dermpath Diagnostics. Also, Quest ( DGX ) will license PathAI's AISight digital pathology image management system to support its pathology laboratories and customer sites. More on Quest Diagnostics Quest Diagnostics: Let's Keep Waiting Quest Diagnostics Incorporated (DGX) Q1 2024 Earnings Call Transcript Quest Diagnostics said to be nearing deal for Canada's Lifelabs Quest Diagnostics to acquire assets of PathAI Diagnostics Seeking Alpha’s Quant Rating on Quest Diagnostics.
